

PATENT APPLICATION

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

Inventors: Ian MacLachlan, a citizen of Canada and the United Kingdom, residing at
8040 Aves Terrace
Mission, B.C., Canada V4S 1E5

Edward Yaworski, a citizen of Canada, residing at
23106 - 123B Avenue
Maple Ridge, B.C., Canada V2X 9Z7

Kieu Lam, a citizen of Canada, residing at
18871 71 Avenue
Surrey, B.C., Canada V4N 5M7

Assignee: Protiva Biotherapeutics, Inc.
100-8900 Glenlyon Parkway
Burnaby, B.C., Canada V5J 5J8

Entity: Large

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] The present application claims priority to U.S. Provisional Application No. 61/045,228, filed April 15, 2008, the disclosure of which is herein incorporated by reference
5 in its entirety for all purposes.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

[0002] Not applicable.

NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT

10 [0003] Not applicable.

REFERENCE TO A "SEQUENCE LISTING"

[0004] Not applicable.

BACKGROUND OF THE INVENTION

[0005] RNA interference (RNAi) is an evolutionarily conserved process in which
15 recognition of double-stranded RNA (dsRNA) ultimately leads to posttranscriptional
suppression of gene expression. This suppression is mediated by short dsRNA, also called
small interfering RNA (siRNA), which induces specific degradation of mRNA through
complementary base pairing. In several model systems, this natural response has been
developed into a powerful tool for the investigation of gene function (*see, e.g., Elbashir et al.,*
20 *Genes Dev.*, 15:188-200 (2001); Hammond *et al., Nat. Rev. Genet.*, 2:110-119 (2001)). More
recently, it was discovered that introducing synthetic 21-nucleotide dsRNA duplexes into
mammalian cells could efficiently silence gene expression.

[0006] Although the precise mechanism is still unclear, RNAi provides a potential new
approach to downregulate or silence the transcription and translation of a gene of interest.
25 For example, it is desirable to modulate (*e.g., reduce*) the expression of certain genes for the
treatment of neoplastic disorders such as cancer. It is also desirable to silence the expression
of genes associated with liver diseases and disorders such as hepatitis. It is further desirable
to reduce the expression of certain genes for the treatment of atherosclerosis and its
manifestations, *e.g., hypercholesterolemia, myocardial infarction, and thrombosis.*

[0007] A safe and effective nucleic acid delivery system is required for RNAi to be therapeutically useful. Viral vectors are relatively efficient gene delivery systems, but suffer from a variety of limitations, such as the potential for reversion to the wild-type as well as immune response concerns. As a result, nonviral gene delivery systems are receiving
5 increasing attention (Worgall *et al.*, *Human Gene Therapy*, 8:37 (1997); Peeters *et al.*, *Human Gene Therapy*, 7:1693 (1996); Yei *et al.*, *Gene Therapy*, 1:192 (1994); Hope *et al.*, *Molecular Membrane Biology*, 15:1 (1998)). Furthermore, viral systems are rapidly cleared from the circulation, limiting transfection to “first-pass” organs such as the lungs, liver, and spleen. In addition, these systems induce immune responses that compromise delivery with
10 subsequent injections.

[0008] Plasmid DNA-cationic liposome complexes are currently the most commonly employed nonviral gene delivery vehicles (Felgner, *Scientific American*, 276:102 (1997); Chonn *et al.*, *Current Opinion in Biotechnology*, 6:698 (1995)). For instance, cationic liposome complexes made of an amphipathic compound, a neutral lipid, and a detergent for
15 transfecting insect cells are disclosed in U.S. Patent No. 6,458,382. Cationic liposome complexes are also disclosed in U.S. Patent Publication No. 20030073640.

[0009] Cationic liposome complexes are large, poorly defined systems that are not suited for systemic applications and can elicit considerable toxic side effects (Harrison *et al.*, *Biotechniques*, 19:816 (1995); Li *et al.*, *The Gene*, 4:891 (1997); Tam *et al.*, *Gene Ther.*,
20 7:1867 (2000)). As large, positively charged aggregates, lipoplexes are rapidly cleared when administered *in vivo*, with highest expression levels observed in first-pass organs, particularly the lungs (Huang *et al.*, *Nature Biotechnology*, 15:620 (1997); Templeton *et al.*, *Nature Biotechnology*, 15:647 (1997); Hofland *et al.*, *Pharmaceutical Research*, 14:742 (1997)).

[0010] Other liposomal delivery systems include, for example, the use of reverse micelles, anionic liposomes, and polymer liposomes. Reverse micelles are disclosed in U.S. Patent No.
25 6,429,200. Anionic liposomes are disclosed in U.S. Patent Publication No. 20030026831. Polymer liposomes that incorporate dextrin or glycerol-phosphocholine polymers are disclosed in U.S. Patent Publication Nos. 20020081736 and 20030082103, respectively.

[0011] A gene delivery system containing an encapsulated nucleic acid for systemic
30 delivery should be small (*i.e.*, less than about 100 nm diameter) and should remain intact in the circulation for an extended period of time in order to achieve delivery to affected tissues. This requires a highly stable, serum-resistant nucleic acid-containing particle that does not interact with cells and other components of the vascular compartment. The particle should

also readily interact with target cells at a disease site in order to facilitate intracellular delivery of a desired nucleic acid.

[0012] Recent work has shown that nucleic acids can be encapsulated in small (*e.g.*, about 70 nm diameter) “stabilized plasmid-lipid particles” (SPLP) that consist of a single plasmid encapsulated within a bilayer lipid vesicle (Wheeler *et al.*, *Gene Therapy*, 6:271 (1999)). These SPLPs typically contain the “fusogenic” lipid dioleoylphosphatidylethanolamine (DOPE), low levels of cationic lipid, and are stabilized in aqueous media by the presence of a poly(ethylene glycol) (PEG) coating. SPLPs have systemic application as they exhibit extended circulation lifetimes following intravenous (*i.v.*) injection, accumulate preferentially at distal tumor sites due to the enhanced vascular permeability in such regions, and can mediate transgene expression at these tumor sites. The levels of transgene expression observed at the tumor site following *i.v.* injection of SPLPs containing the luciferase marker gene are superior to the levels that can be achieved employing plasmid DNA-cationic liposome complexes (lipoplexes) or naked DNA.

[0013] Thus, there remains a strong need in the art for novel and more efficient methods and compositions for introducing nucleic acids such as siRNA into cells. In addition, there is a need in the art for methods of downregulating the expression of genes of interest to treat or prevent diseases and disorders such as cancer and atherosclerosis. The present invention addresses these and other needs.

BRIEF SUMMARY OF THE INVENTION

[0014] The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (*e.g.*, for the treatment of a disease or disorder).

[0015] In preferred embodiments, the active agent or therapeutic agent is fully encapsulated within the lipid portion of the lipid particle such that the active agent or therapeutic agent in the lipid particle is resistant in aqueous solution to enzymatic degradation, *e.g.*, by a nuclease or protease. In other preferred embodiments, the lipid particles are substantially non-toxic to mammals such as humans.

[0016] In one aspect, the present invention provides lipid particles comprising: (a) one or more active agents or therapeutic agents; (b) one or more cationic lipids comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) one or more non-cationic lipids comprising from about 13 mol % to about 49.5 mol % of the total lipid

present in the particle; and (d) one or more conjugated lipids that inhibit aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

5 [0017] More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (*e.g.*, one or more interfering RNA molecules such as siRNA, aiRNA, and/or miRNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP (*e.g.*, for the treatment of a disease or disorder).

10 [0018] In certain embodiments, the nucleic acid-lipid particle (*e.g.*, SNALP) comprises: (a) a nucleic acid (*e.g.*, an interfering RNA); (b) a cationic lipid comprising from about 50 mol % to about 85 mol % of the total lipid present in the particle; (c) a non-cationic lipid comprising from about 13 mol % to about 49.5 mol % of the total lipid present in the particle; and (d) a conjugated lipid that inhibits aggregation of particles comprising from about 0.5 mol % to about 2 mol % of the total lipid present in the particle.

15 [0019] In one preferred embodiment, the nucleic acid-lipid particle (*e.g.*, SNALP) comprises: (a) an siRNA; (b) a cationic lipid comprising from about 56.5 mol % to about 66.5 mol % of the total lipid present in the particle; (c) cholesterol or a derivative thereof comprising from about 31.5 mol % to about 42.5 mol % of the total lipid present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle. This preferred embodiment of nucleic acid-lipid particle
20 is generally referred to herein as the “1:62” formulation.

[0020] In another preferred embodiment, the nucleic acid-lipid particle (*e.g.*, SNALP) comprises: (a) an siRNA; (b) a cationic lipid comprising from about 52 mol % to about 62 mol % of the total lipid present in the particle; (c) a mixture of a phospholipid and cholesterol or a derivative thereof comprising from about 36 mol % to about 47 mol % of the total lipid
25 present in the particle; and (d) a PEG-lipid conjugate comprising from about 1 mol % to about 2 mol % of the total lipid present in the particle. This preferred embodiment of nucleic acid-lipid particle is generally referred to herein as the “1:57” formulation.

[0021] The present invention also provides pharmaceutical compositions comprising a lipid particle described herein (*e.g.*, SNALP) and a pharmaceutically acceptable carrier.

30 [0022] In another aspect, the present invention provides methods for introducing an active agent or therapeutic agent (*e.g.*, nucleic acid) into a cell, the method comprising contacting the cell with a lipid particle described herein such as a nucleic acid-lipid particle (*e.g.*, SNALP).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.